Care of Transgender and Gender Diverse Patients in Primary Care

Jenny Siegel, MD

Assistant Professor of Medicine, Boston University School of Medicine Section of General Internal Medicine, Boston Medical Center Medical Director, Center for Transgender Medicine & Surgery



Jennifer.siegel@bmc.org

Annie Potter, MSN, MPH, FNP-C, CARN-AP

Assistant Professor of Medicine, Boston University School of Medicine Section of General Internal Medicine, Boston Medical Center Center for Transgender Medicine & Surgery



Annie.Potter@bmc.org

February 3, 2022

Disclosures

- No relationships or commercial interests to disclose.
- Some medications discussed are used for gender-affirming hormone therapy on an off-label basis.



Learning Objectives

- 1. Consider how transgender health is a fundamental component of primary care
- 2. Brief review of terminology related to gender identity
- 3. Recognize the holistic needs of transgender populations inclusive of preventative and gender-affirming medical care.



Our Pragmatic Hopes

That after this talk you will feel more comfortable:

- Greeting patients with inclusive language
- Discussing patient goals for gender affirmation
- Offering psychosocial support to your patients
- Providing routine preventive health care to transgender/gender diverse patients
- Helping with documentation for name/gender marker changes
- Prescribing gender-affirming hormones in primary care





Transgender Health is Primary Care

Wellness promotion

- Role of gender identity/gender affirmation in overall health
- Inclusive preventive screening

Psychosocial Context

- Address mental health, social supports
- Resources for legal/social transition

Chronic Health Management

- Gender-affirming medications
- Addressing concurrent health conditions

Inter-professional Teamwork


- Pharmacy injection supplies
- Electronic medical record

Engagement with Specialists

- Endocrine, behavioral health, surgery, voice therapy, dermatology
- Medical records, legal services, social work



Sexual Orientation vs. Gender Identity







Terminology - Gender

Gender identity - one's innermost concept of self as male, female, a blend of both or neither – how individuals perceive themselves and what we call themselves.

Gender expression - external appearance of one's gender identity, usually expressed through behavior, clothing, haircut or voice. May be on a spectrum.

Cisgender - gender identity is aligned with sex assigned at birth.

Transgender - umbrella term for people whose gender identity and/or expression is different from cultural expectations based on the sex they were assigned at birth.

Nonbinary/gender non-conforming/gender diverse/genderqueer – all terms that describe those who do not have a binary gender identity

bans-1,2-dichloroethene

c/s-1,2-dichloroethene



How Many?







How Many?

Americans' Self-Identified Sexual Orientation

Which of the following do you consider yourself to be? You can select as many as apply: Straight or heterosexual; Lesbian; Gay; Bisexual; Transgender.

	Among LGBT U.S. adults	Among all U.S. adults
	%	%
Lesbian	11.7	0.7
Gay	24.5	1.4
Bisexual	54.6	3.1
Transgender	11.3	0.6
Other (e.g., queer, same-gender-loving)	3.3	0.2

 $Percentages\ total\ more\ than\ 100\%\ because\ respondents\ may\ choose\ more\ than\ one\ category.$

GALLUP, 2020






Health Inequities

- Higher prevalence of overall poor health
- 40% (vs 5%) serious psychological distress
- 40% (vs 4.6%) lifetime suicide attempt
- 50% bullying in school
- Less likely to have regular health insurance or regular health provider
- No difference in burden of chronic illness

Figure 7.43: Living with HIV among transgender women RACE/ETHNICITY (%)



Flores, A.R., Herman, J.L., Gates, G.J., & Brown, T.N.T. (2016). How Many Adults Identify as Transgender in the United States? Los Angeles, CA: The Williams Institute.

Meyer IH, Brown TN, Herman JL, Reisner SL, Bockting WO. Demographic Characteristics and Health Status of Transgender Adults in Select US Regions: Behavioral Risk Factor Surveillance System, 2014.

Am J Public Health. 2017 Apr;107(4):582-589. doi: 10.2105/AJPH.2016.303648. Epub 2017 Feb 16. PMID: 28207334; PMCID: PMC5343705.





Health Care Access and Behavioral Health

There is a protective effect on mental health status and substance use for trans women who utilize transition-related medical care:

- Utilization of hormones, breast augmentation, and genital surgery were all associated with lower odds of suicidal ideation, binge drinking, and non-injection drug use
- A history of gender-affirming surgery was associated with lower odds of psychological distress, tobacco smoking, and suicidal ideation as compared with no history of gender-affirming surgery

Wilson et al., 2015 Almazan & Keuroghlian, 2021







Creating a Welcoming Environment

- Display symbols welcoming LGBTQ community
- Include brochures addressing relevant health concerns
- Update intake forms/EMRs
- Staff training re: gender neutral language
- ASK
 - Correct name
 - Pronouns
 - Language for body (anatomy)
- Recognize that much care being sought is not specifically related to gender

GLMA. Guidelines for Caring for Lesbian, Gay, Bisexual, Transgender Patients.







More Tips for Inclusive Language

Instead of "Nice to meet you, sir"

• Try "Nice to meet you"

Instead of "I see here your name is XXX"


• Try "Hi, I'm XX, how should I address you during our visit today"

Instead of "we still need to examine your female organs"

• Try "Can we talk about why a pap test is indicated for you?"

Instead of "Women and Transgender Women"

- Try Cisgender Women and Transgender Women or just Women
- Avoid describing cisgender individuals as "normal" or "regular"







Gender Transition or Affirmation Process

Psychological (sense of self)

Medical (hormone therapy)

Social (outward expression)

Surgical

Legal (identity documents)







Changing Identity Documents

- Rules vary widely between states
 - Physician/provider letter often needed for <u>gender</u> <u>marker</u> changes
 - National Center for Transgender Equality provides state-by-state guidance
 - In MA for drivers license/state ID
 - Federally birth certificate, Soc Security card
 - "appropriate clinical treatment for gender transition"
- Significant delays with COVID-19
- Birth certificate changes require notary
- Changes are linked with better mental health

Letter Certifying Applicant's Gender Change					
l,(Physician's Full Name)					
(Physician's medical license/certificate number)	(Issuing State/Country of license/certificate)				
am the physician of					
(Date of Birth of Patient)					
with whom I have a doctor/patient relationship and whom I have treated, or with whom I have a doctor/patient relationship and whose medical history I have reviewed and evaluated.					
(Name of Patient)	1				
has had appropriate clinical treatment fo	or transition to 🗆 male 🗆 female.				
I declare under penalty of perjury under foregoing is true and correct.	the laws of the United States that the				
Signature of Physician	Physician's Address				
Typed Name of Physician	Date				
Physician's Phone Number					









Taking a Gender History





Providing Psychosocial Support

- Earning patient trust
- Assessing social determinants of health (good primary care) and connecting to resources
 - Working with social work, case management, and patient navigators
- Discuss mental health and well-being
 - Mental health services are not required to access gender-affirming medical interventions at Boston Medical Center
- Connect to services when requested or required
 - Specific requirement for Gender-affirming surgical interventions
 - Many interested in a variety of other behavioral health services





Gender Affirming Hormones: Before you Start

Models of Care

• "Gatekeeping" vs. Informed Consent

Diagnosis

- Gender Dysphoria
- Gender Incongruence

Individualize Treatment Goals

 Medications, surgery, hair removal, behavioral health, other

Fertility Preservation

- Discuss before starting hormones
- Be aware of insurance issues





Hormone Therapy - Adults

Goals of therapy:

- Reduce endogenous sex hormone levels
- Replace with exogenous sex hormones that will support the expressed gender identity


Transgender males

- Testosterone
- Goals: testosterone 400-800 ng/dL, estradiol <50 pg/mL and cessation of menses

Transgender females

- Estrogen replacement
- Androgen blockers
- Goal estradiol level 100-200 pg/mL and testosterone <50 ng/dL

Nonbinary/Gender Diverse Individuals







Masculinizing Regimens

Androgen	Initial - low dose ^b	Initial - typical	Maximum - typical ^c	Comment
Testosterone Cypionate ^a	20 mg/week IM/SQ	50mg/week IM/SQ	100mg/week IM/SQ	For q 2 wk dosing, double each dose
Testosterone Enthanate ^a	20mg/week IM/SQ	50mg/week IM/SQ	100mg/week IM/SQ	n
Testosterone topical gel 1%	12.5-25 mg Q AM	50mg Q AM	100mg Q AM	May come in pump or packet form
Testosterone topical gel 1.62% ^d	20.25mg Q AM	40.5 - 60.75mg Q AM	103.25mg Q AM	"
Testosterone patch	1-2mg Q PM	4mg Q PM	8mg Q PM	Patches come in 2mg and 4mg size. For lower doses, may cut patch

https://transcare.ucsf.edu/guidelines





Masculinizing Effects

Table 12. Masculinizing Effects in Transgender Males

Effect	Onset	Maximum
Skin oiliness/acne	1–6 mo	1–2 y
Facial/body hair growth	6-12 mo	4–5 y
Scalp hair loss	6-12 mo	a´
Increased muscle mass/strength	6-12 mo	2–5 y
Fat redistribution	1–6 mo	2–5 y
Cessation of menses	1–6 mo	b
Clitoral enlargement	1–6 mo	1–2 y
Vaginal atrophy	1–6 mo	1–2 y
Deepening of voice	6–12 mo	1–2 y

Estimates represent clinical observations: Toorians et al. (149), Asscheman et al. (156), Gooren et al. (157), Wierckx et al. (158).

Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T'Sjoen, G. G. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: An endocrine society*clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*, 102(11), 3869–3903. https://doi.org/10.1210/jc.2017-01658





Hormone Therapy – Goal Serum Levels

Goals of therapy:

- Reduce endogenous sex hormone levels
- Replace with exogenous sex hormones that will support the expressed gender identity


Transgender males

- Testosterone
- Goals: testosterone 400-800 ng/dL, estradiol <50 pg/mL and cessation of menses

Transgender females

- Estrogen replacement
- Androgen blockers
- Goal estradiol level 100-200 pg/mL and testosterone <50 ng/dL

Nonbinary/Gender Diverse Individuals







Masculinizing Hormones – Challenges

- Persistent menses
- Erythrocytosis
- Lipid changes (↓ HDL, ↑ TG)
- Liver dysfunction (transaminases > 3x ULN)
- Acne
- Worsening of hypertension
- Mood and Energy changes
- Male Pattern Baldness

Contraindications:

- Pregnancy
- Hormone sensitive cancer
- Frank polycythemia (Hct >55%)





Feminizing Regimens

Hormone	Initial- Iow ^b	Initial	Maximum^c	Comments	
Estrogen					
Estradiol oral/sublingual	1mg/day	2- 4mg/day	8mg/day	if >2mg recommend divided bid dosing	
Estradiol transdermal	50mcg	100mcg	100-400 mcg	Max single patch dose available is 100mcg. Frequency of change is brand/product dependent. More than 2 patches at a time may be cumbersome for patients	
Estradiol valerate IM ^a	<20mg IM q 2 wk	20mg IM q 2 wk	40mg IM q 2wk	May divide dose into weekly injections for cyclical symptoms	
Estradiol cypionate	<2mg q 2wk	2mg IM q 2 wk	5mg IM q 2 wk	May divide dose into weekly injections for cyclical symptoms	
Androgen blocker					
Spironolactone	25mg qd	50mg bid	200mg bid		

https://transcare.ucsf.edu/guidelines





Feminizing Effects

Table 13. Feminizing Effects in Transgender Females

Effect	Onset	Maximum
Redistribution of body fat	3–6 mo	2–3 y
Decrease in muscle mass and strength	3–6 mo	1–2 y
Softening of skin/decreased oiliness	3–6 mo	Unknown
Decreased sexual desire	1–3 mo	3–6 mo
Decreased spontaneous erections	1–3 mo	3–6 mo
Male sexual dysfunction	Variable	Variable
Breast growth	3–6 mo	2–3 y
Decreased testicular volume	3–6 mo	2–3 y
Decreased sperm production	Unknown	>3 y
Decreased terminal hair growth	6–12 mo	$>3 y^a$
Scalp hair	Variable	b
Voice changes	None	_c

hates represent clinical observations: Toorians et al. (149), Asscheman et al. (156), Gooren et al. (157).

Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T'Sjoen, G. G. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: An endocrine society*clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*, 102(11), 3869–3903. https://doi.org/10.1210/jc.2017-01658





Hormone Therapy – Goal Serum Levels

Goals of therapy:

- Reduce endogenous sex hormone levels
- Replace with exogenous sex hormones that will support the expressed gender identity


Transgender males

- Testosterone
- Goals: testosterone 400-800 ng/dL, estradiol <50 pg/mL and cessation of menses

Transgender females

- Estrogen replacement
- Androgen blockers
- Goal estradiol level 100-200 pg/mL and testosterone <50 ng/dL

Nonbinary/Gender Diverse Individuals







Challenges with Feminizing Hormones

Side Effects

- Estrogen
 - Headache
 - Mood swings
 - Weight Gain
- Spironolactone
 - Polyuria
 - Orthostasis

Complications

- Venous Thromboembolism
- Prolactinoma
- +/- cardiovascular effects
- Changes in Libido
- Migraines
- Mental Health





Gender Affirming Hormones & CV Risk

Study	Outcomes Finding		igs F/U		Limitations: data not included	
Study	Outcomes	TW	TM	yrs *	Limitations. data not included	
Nota	VTE	+++	NS		tobacco	
2517 TW	MI	NS	+++	9±9	comorbid conditions	
1358 TM	Stroke	+++	NS	8±9	aspirin, statin	
Getahun	VTE	+++	NS		comorbid conditions	
2842 TW	MI	NS	NS	4±3		
853 TM	Stroke	+++	NS	4±3	aspirin, statin	
Asscheman	VTE	+++	NS		tobacco	
966 TW	MI	NS	NS	19±8	comorbid conditions	
365 TM	Stroke	NS	NS	19±6	aspirin, statin	

TM = Transgender men; TW = Transgender women; F/U = mean follow up;
VTE = venothromboembolism; MI = myocardial infarction; NS = no significant finding;
(+++) = significant increased risk of outcome, *mean ± SD yr follow-up

Andrologia 2014;46:791. Ann Intern Med 2018;169:205. Circulation 2019;139:1461.





Non-binary and Gender Diverse Individuals

- Adjust doses of spironolactone and/or estradiol to maintain testosterone levels in a range between standard male and female levels
- Use of anti-androgens alone
 - BUT WATCH FOR BONE LOSS!
- Limited courses of hormone therapy
- Surgical affirmation without hormone treatment







Surgical Options

Trans Feminizing

- Breast augmentation
- Genital Surgeries
 - Vaginoplasty with orchiectomy
 - Genital remodeling
- Vocal Cord Procedures
- Facial feminization
 - Forehead and brow bone reshaping
 - Jaw and chin contouring
 - Rhinoplasty
 - Hairline changes
 - Tracheal shave

Trans Masculinizing

- Chest reconstruction
- Hysterectomy +/- BSO
- Metoidioplasty (creating phallus from clitoral tissue)
- Phalloplasty (creating phallus from other part of the body, such as from a radial forearm flap)





Preventive Care

Cancer Screening

Screen all organs that are present in line with national guidelines

Substance Use and Mental Health Screening

Consider screening for depression/anxiety

Assessment for unhealthy substance use

Bone Health

Consider Hx of blockers, anti-androgens without estrogen, +/- gonads

Osteoporosis: consider screening at baseline if risk factors for osteoporotic fracture present

Sexual Health

Thorough sexual history taking

Comprehensive STI screening

Contraceptive Needs

Vaccinations

Cardiovascular Risk Assessment/Mitigation

Challenges include sex-specific calculators













Helpful Guidelines & Learning More

 UCSF Guidelines for Primary and Gender-Affirming Care <u>https://transcare.ucsf.edu/guidelines</u>

Transgender Health ECHO
 https://www.lgbtqiahealtheducation.org/project-echo/trans-echo/

Project Health TransLine
 http://project-health.org/transline/





WPATH ==

Standards of Care



Center for Transgender Medicine and Surgery







Questions?





